Navigation Links
Major advanced cancer study to be led by Uppsala University
Date:8/18/2011

Several prominent cancer researchers are now joining forces in an advanced new cancer study. The goal is to understand which tumors will be difficult to treat and to find out why certain cancer drugs lose their effect after a period of use. The study is to be directed by Tobias Sjblom, associate professor of tumor biology at Uppsala University, Sweden.

The study involves a hundred cancer patients, suffering from either cancer of the large intestine or chronic lymphatic leukemia. Samples will be taken from patients both before and after drug treatment. The aim is to find out what makes so many tumors resistant to treatment a major problem in cancer care today.

"With this initiative we will have a unique opportunity to study the development of tumors up close. Several research teams will examine the samples using different analytical methods in order to get an overall picture," says Tobias Sjblom, associate professor of tumor biology at Uppsala University and director of the study.

What lies behind this resistance is not known today, but it is assumed to emerge when the tumor changes over time, mutates. This also alters the original approach to treatment. In the study scientists will be looking for mutations in all the genes in the tumors.

The study is to be performed by Uppsala scientists together with colleagues from the Royal Institute of Technology, the Swedish University of Agricultural Sciences, and Ume University. It is made possible by funding from SciLifeLab, a total of SEK 4.5 million over two years. All analyses will be done at SciLifeLab, which is a national resource center for medical and bioscience research.

"This is a model for how we want to work with large projects within SciLifeLab. Researchers receiving funding from us have access to our resources in the form of technologically advanced equipment and competence, while their own expertise in the specific research field ensures that the right questions are being asked. This enables us to generate new knowledge about diseases more quickly," says Kerstin Lindblad-Toh, director of SciLifeLab Uppsala.

This type of research is also of interest to the pharmaceuticals industry.

"The industry will have an opportunity to assess the effect of their drugs, and we hope this will provide greater insights into how we can predict how different patients will react to a certain medicine in the future," says Tobias Sjblom.


'/>"/>

Contact: Tobias Sjblom
tobias.sjoblom@igp.uu.se
46-070-167-9039
Uppsala University
Source:Eurekalert

Related medicine news :

1. Seattle Childrens lands major funding with hopes of saving thousands of infant lives
2. Group Health establishes major initiative to prevent opioid abuse and overdose
3. Nottingham scientist wins major cancer research award
4. Major award for leading expert in regenerative medicine
5. Obesity a Major Cause of Early Death in Women: Study
6. Major malaria drug research award
7. Lawmakers Urged to Consider Health Effects of Major Legislation
8. Government should consider public health implications of all major legislation
9. Deaths and major morbidity from asbestos-related diseases in Asia likely to surge in next 20 years
10. UB played major role in study on drug that reduces breast cancer in high-risk women
11. New advances in lipid genetics lead to better detection and prevention of major diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a ... Migraine Relief with the 2017 Women’s Choice Award. The identification by women of an ... out of 4 migraine sufferers are women. In a survey taken by the Women’s ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... good health is as simple as eating healthy foods. But this well-known piece ... fat, making insulin, or breaking apart carbohydrates—depends not only on properties of the ...
(Date:8/22/2017)... ... 22, 2017 , ... Western North Carolina’s only certified fellow ... aesthetics conference for medical professionals about the positive impact Juliet™ feminine rejuvenation ... practice. , Dr. George K. Ibrahim shared the results of his ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot ... addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch ... firm’s national accounts, from assisting clients with initial vendor selection and pre-implementation planning ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has sent ... these labels and stickers, demonstrating the variety and creativity of their designs. Submissions this year ... came in. Now, it's time to announce the winners of the sixth annual Photo Contest, ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 7D Surgical, developer of ... has purchased the 7D Surgical System to support its strategic ... Washington D.C. and Virginia.  7D Surgical has entered ... many of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
Breaking Medicine Technology: